2 completed, 1 not yet recruiting, 1 unknown. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Not yet recruiting 1, Unknown 1 |
Follow NPI 2358: new trials by email Literature Review of NPI 2358 trials Research Report on NPI 2358
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) Plinabulin, Docetaxel, Placebo (matching plinabulin placebo) - Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance | Phase 3 | Not yet recruiting | BeyondSpring Pharmaceuticals Inc. | 442 | 2026-12-01 | 2026-09-29 |
| Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia Pegfilgrastim, Plinabulin, D5W Placebo - Chemotherapy-induced Neutropenia | Phase 3 | Unknown | BeyondSpring Pharmaceuticals Inc. | 221 | 2019-10-23 | 2021-01-15 |
| Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 Plinabulin, Pegfilgrastim, Saline Placebo - Chemotherapy-induced Neutropenia | Phase 3 | Completed | BeyondSpring Pharmaceuticals Inc. | 105 | 2018-05-29 | 2024-08-29 |
| Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC Docetaxel + Plinabulin (DP), Docetaxel (D) - Non-Small Cell Lung Cancer | Phase 3 | Completed | BeyondSpring Pharmaceuticals Inc. | 559 | 2015-12-01 | 2026-05-19 |
Carcinoma, Non-Small-Cell Lung (2)
BeyondSpring Pharmaceuticals Inc. (4)
China (3) · Ukraine (2) · United States (2) · Australia (1) · Russia (1)
Douglas Blayney, M.D. (1) · Douglas W. Blayney, MD (1)